https://www.globenewswire.com/news-release/2024/10/15/2963013/0/en/Junshi-Biosciences-Announces-Toripalimab-Obtained-Approval-for-Marketing-in-India-and-China-s-Hong-Kong-SAR.html
Junshi Biosciences Announces Toripalimab Obtained Approval
SHANGHAI, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
junshibiosciencesannouncestoripalimabobtained
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.878851/full
Frontiers | Toripalimab in Combination With Induction Chemotherapy and Subsequent Chemoradiation as...
Introduction: Immune checkpoint inhibitor therapy combined with chemotherapy is safe and effective in treating advanced esophageal carcinoma; however, some p...
induction chemotherapyfrontierstoripalimabcombination
https://pmc.ncbi.nlm.nih.gov/articles/PMC11982770/
Evaluation of the efficacy and safety of toripalimab combination therapy for treatment of advanced...
Background: To systematically evaluate the efficacy and safety of combination therapy with toripalimab in the treatment of advanced gastric cancer (GC)....
efficacy and safetyof the
https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1131219/full
Frontiers | Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell...
Background: The potency and safety of toripalimab combination with chemotherapy (TC) as the first-line therapy for advanced NSCLC have been demonstrated in t...
in patients
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1113389/full
Frontiers | Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma...
OBJECTIVE: Exposing tumor antigens to the immune system is the key to ensuring the efficacy of immunotherapy. SBRT is the main way to reveal the specifical a...
frontierstoripalimabcombinationanlotinibunresectable